Latest Balance Sheet News

Mont Royal Resources Limited reported a stable cash position of $1.75 million at the end of December 2024, despite significant outflows on exploration activities during the quarter.

E79 Gold Mines Limited reported a $169,000 net cash outflow from operating activities for the December 2024 quarter, maintaining a solid cash balance of $1.46 million as it continues its exploration efforts.

Gateway Mining Ltd has fortified its balance sheet through the sale of its Eastern Montague Gold Project, positioning itself for an aggressive exploration campaign in 2025 focused on the Barrelmaker Gold and Montague Range Base Metals projects in Western Australia.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Skylark Minerals has reshaped its leadership team with seasoned gold industry veterans and agreed to divest its Citronen Zn-Pb Project, positioning the company for renewed growth and exploration success.

Arrow Minerals has secured $7 million through a well-supported placement to advance its flagship Niagara Bauxite and Simandou North Iron projects in Guinea, setting the stage for key resource milestones and development studies.

Nelson Resources bolstered its balance sheet with a $2.3 million placement and appointed Dr Louis Bucci as Executive Director, setting the stage for renewed exploration at its Fortnum and Yarri gold projects in early 2025.

Babylon Pump & Power Ltd reports robust H1 FY25 results with $1.8M positive operating cash flow and $3.0M EBITDA, overcoming nickel sector challenges. The company eyes growth through new projects and acquisitions.

Whitehaven Coal delivered a robust Q2 FY25 with record sales volumes and production costs at the low end of guidance, while preparing for a major $1.08 billion capital inflow from its Blackwater mine stake sale.

Aroa Biosurgery has reported its first quarter of positive operating cash flow since listing on the ASX in 2020, alongside robust revenue growth projections and new regulatory approvals across key international markets.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

Aurelia Metals delivers a robust December 2024 quarter, hitting key production targets and marking a milestone with first concentrate from its Federation ore. The company maintains a strong balance sheet while advancing growth projects.